A diagnostic and therapeutic approach to primary burning mouth syndrome

Siamak Moghadam-Kia, Nasim Fazel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Primary burning mouth syndrome (BMS) is an oral mucosal disorder that is characterized by a chronic and often debilitating intraoral burning sensation for which no localized or systemic cause can be found. BMS most commonly affects postmenopausal women. The pathophysiology of primary BMS is not well understood. Diagnosing BMS can prove to be challenging. BMS patients can also pose a therapeutic challenge to clinicians who are consulted to evaluate these patients. Most commonly used therapies include tricyclic antidepressants, α-lipoic acid, clonazepam, and cognitive-behavioral therapy. Clinical judgment, patient counseling, and monitoring of pain are important. Further research is required to assess the effectiveness of serotonin and newer serotonin-noradrenalin reuptake inhibitors.

Original languageEnglish (US)
Pages (from-to)453-460
Number of pages8
JournalClinics in Dermatology
Volume35
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Burning Mouth Syndrome
Therapeutics
Clonazepam
Thioctic Acid
Tricyclic Antidepressive Agents
Physiologic Monitoring
Cognitive Therapy
Counseling
Serotonin
Pain
Research

ASJC Scopus subject areas

  • Dermatology

Cite this

A diagnostic and therapeutic approach to primary burning mouth syndrome. / Moghadam-Kia, Siamak; Fazel, Nasim.

In: Clinics in Dermatology, Vol. 35, No. 5, 01.09.2017, p. 453-460.

Research output: Contribution to journalArticle

@article{e532c5081bd747b5a1fd3704392d66ab,
title = "A diagnostic and therapeutic approach to primary burning mouth syndrome",
abstract = "Primary burning mouth syndrome (BMS) is an oral mucosal disorder that is characterized by a chronic and often debilitating intraoral burning sensation for which no localized or systemic cause can be found. BMS most commonly affects postmenopausal women. The pathophysiology of primary BMS is not well understood. Diagnosing BMS can prove to be challenging. BMS patients can also pose a therapeutic challenge to clinicians who are consulted to evaluate these patients. Most commonly used therapies include tricyclic antidepressants, α-lipoic acid, clonazepam, and cognitive-behavioral therapy. Clinical judgment, patient counseling, and monitoring of pain are important. Further research is required to assess the effectiveness of serotonin and newer serotonin-noradrenalin reuptake inhibitors.",
author = "Siamak Moghadam-Kia and Nasim Fazel",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.clindermatol.2017.06.006",
language = "English (US)",
volume = "35",
pages = "453--460",
journal = "Clinics in Dermatology",
issn = "0738-081X",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - A diagnostic and therapeutic approach to primary burning mouth syndrome

AU - Moghadam-Kia, Siamak

AU - Fazel, Nasim

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Primary burning mouth syndrome (BMS) is an oral mucosal disorder that is characterized by a chronic and often debilitating intraoral burning sensation for which no localized or systemic cause can be found. BMS most commonly affects postmenopausal women. The pathophysiology of primary BMS is not well understood. Diagnosing BMS can prove to be challenging. BMS patients can also pose a therapeutic challenge to clinicians who are consulted to evaluate these patients. Most commonly used therapies include tricyclic antidepressants, α-lipoic acid, clonazepam, and cognitive-behavioral therapy. Clinical judgment, patient counseling, and monitoring of pain are important. Further research is required to assess the effectiveness of serotonin and newer serotonin-noradrenalin reuptake inhibitors.

AB - Primary burning mouth syndrome (BMS) is an oral mucosal disorder that is characterized by a chronic and often debilitating intraoral burning sensation for which no localized or systemic cause can be found. BMS most commonly affects postmenopausal women. The pathophysiology of primary BMS is not well understood. Diagnosing BMS can prove to be challenging. BMS patients can also pose a therapeutic challenge to clinicians who are consulted to evaluate these patients. Most commonly used therapies include tricyclic antidepressants, α-lipoic acid, clonazepam, and cognitive-behavioral therapy. Clinical judgment, patient counseling, and monitoring of pain are important. Further research is required to assess the effectiveness of serotonin and newer serotonin-noradrenalin reuptake inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85031127715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031127715&partnerID=8YFLogxK

U2 - 10.1016/j.clindermatol.2017.06.006

DO - 10.1016/j.clindermatol.2017.06.006

M3 - Article

C2 - 28916026

AN - SCOPUS:85031127715

VL - 35

SP - 453

EP - 460

JO - Clinics in Dermatology

JF - Clinics in Dermatology

SN - 0738-081X

IS - 5

ER -